Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.52 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910523 | 0.92 | SMN1; SMN2 (0.56) | MMP13RAB9ASMN1; SMN2NPC1HTT | |
| SCHEMBL15387841 | 0.90 | APEX1 (0.55) | MMP13RAB9ASMN1; SMN2NPC1HTT | |
| SCHEMBL2909519 | 0.89 | PPARG (0.56) | MMP13RAB9ASMN1; SMN2NPC1HTT | |
| SCHEMBL3766516 | 0.89 | RXRA (0.65) | RAB9ASMN1; SMN2NPC1HTTTP53 | |
| SCHEMBL2909026 | 0.87 | NR4A2 (0.63) | RAB9ASMN1; SMN2NPC1HTTMRGPRX4 | |
| SCHEMBL2908779 | 0.85 | NR4A2 (0.65) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL2905853 | 0.84 | NR4A2 (0.62) | RAB9ASMN1; SMN2NPC1HTTMRGPRX4 | |
| SCHEMBL2908929 | 0.83 | NPC1 (0.57) | RAB9ASMN1; SMN2NPC1HTTTP53 | |
| SCHEMBL12999002 | 0.82 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPC1HTTTP53 | |
| SCHEMBL2909423 | 0.82 | PTGER4 (0.55) | TOP2APOLBPTGER4RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | claimed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | claimed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | claimed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | claimed |
| EP-2220029-B1 | Benzamide compounds and their use as prostaglandin E4 receptor agonists | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-8293798-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-10-23 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| US-20100305166-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-12-02 | — | — | US | disclosed |
| EP-2220029-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009056582-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305166-A1 | NOVEL COMPOUNDS | F12, C1R, RPS4X | MMP13 4500/4885RAB9A 733/4885SMN1; SMN2 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.